Observational studyJournal of the American Heart Association2020
Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study.
Observational study in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis.Current cardiology reviews · 2023Pooled it
- Association between galectin-3 and echocardiographic changes in hospitalized patients with coronavirus disease 2019: A retrospective observational study.The Journal of international medical research · 2026Observational
- From Oxidative Stress to Fibrotic Remodeling: Integrating Redox Biology, Galectin-3, and Imaging Phenotypes in Heart Failure.Antioxidants (Basel, Switzerland) · 2026Review
- Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.Journal of the American Heart Association · 2026Article
- Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.Biomedicines · 2026Review
- Wash, Rinse, Repeat: Moving Galectin-3 From Research to Clinical Practice.Kidney medicine · 2026Article
- Galectin-3 and Cardio-Kidney Outcomes: A Bit of History Repeating.Kidney medicine · 2026Article
- Circulating biomarkers and mortality in atrial fibrillation: the REasons for Geographic And Racial Differences in Stroke study.European heart journal open · 2026Article
- Article
- The Role of Galectin-3 in Atherosclerosis and Its Cardiovascular Complications: An Update.Journal of lipid and atherosclerosis · 2026Review
- Assessment of Cardiovascular Risk in the PURE Poland Cohort Study Using the Systematic Coronary Risk Evaluation (SCORE) Scale and Galectin-3 Concentrations: A Cross-Sectional Study.International journal of molecular sciences · 2025Article
- Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases.Scientific reports · 2024Article
- Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2024Article
- Cardiovascular Disease and Alzheimer's Disease: The Heart-Brain Axis.Journal of the American Heart Association · 2023Review
- Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis.Frontiers in cardiovascular medicine · 2023Review
- Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2022Article
- Association between circulating Galectin-3 and arterial stiffness in older adults.VASA. Zeitschrift fur Gefasskrankheiten · 2021Article
- The serum galectin-3 levels are associated with the severity and prognosis of ischemic stroke.Aging · 2021Article
- Galectin-3 in Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study.Journal of the American Heart Association · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Background Circulating galectin-3 levels provide prognostic information in patients with established heart failure (HF), but the associations between galectin-3 levels and other incident cardiovascular events in asymptomatic individuals at midlife and when remeasured ≈15 years later are largely uncharacterized. Methods and Results Using multivariable Cox proportional hazards models, we identified associations between plasma galectin-3 levels (hazard ratio [HR] per 1 SD increase in natural log galectin-3) and incident coronary heart disease, ischemic stroke, HF hospitalization, and total mortality in ARIC (Atherosclerosis Risk in Communities) participants free of cardiovascular disease at ARIC visit 4 (1996-1998; n=9247) and at ARIC visit 5 (2011-2013; n=4829). Higher galectin-3 level at visit 4 (median age 62) was independently associated with incident coronary heart disease (adjusted HR, 1.30; 95% CI, 1.06-1.60), ischemic stroke (HR, 1.42; 95% CI, 1.01-2.00), HF (HR, 1.44; 95% CI, 1.17-1.76), and mortality (HR, 1.56; 95% CI, 1.35-1.80). At visit 5 (median age, 74), higher galectin-3 level was associated with incident HF (HR, 1.93; 95% CI, 1.15-3.24) and total mortality (HR, 1.70; 95% CI, 1.15-2.52), but not coronary heart disease or stoke. Individuals with the greatest increase in galectin-3 levels from visit 4 to visit 5 were also at increased risk of incident HF and total mortality. Conclusions In a large, biracial community-based cohort, galectin-3 measured at midlife and older age was associated with increased risk of cardiovascular events. An increase in galectin-3 levels over this period was also associated with increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.